INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

(marketscreener.com) Immunological data from recently completed Phase 1b trial will be presented on April 16thPLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases,...https://www.marketscreener.com/quote/stock/INOVIO-PHARMACEUTICALS-I-17937428/news/INOVIO-Announces-Acceptance-of-Abstract-for-Oral-Presentation-on-INO-4201-as-an-Ebola-Booster-for-rV-43475613/?utm_medium=RSS&utm_content=20230412